SLC5A2 and atherosclerosis: While statins and SGLT2 inhibitors have demonstrated clear benefits in reducing ASCVD risk, PTX’s unique mechanism—especially its influence on Klotho and ROS—may provide an additional therapeutic benefit, particularly in patients who are refractory to standard treatments.